CytoDyn (CYDY)
(Delayed Data from OTC)
$0.14 USD
0.00 (-1.20%)
Updated Jul 24, 2024 03:53 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CYDY 0.14 0.00(-1.20%)
Will CYDY be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CYDY based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for CYDY
CytoDyn Announces Settlement with Amarex Clinical Research LLC
CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024
CytoDyn announces start of preclinical MASH study
CytoDyn to Host Webcast to Provide Company Update
May 2024 Letter to Shareholders